Telisotuzumab vedotin (ADC)
Telisotuzumab vedotin is an ADC consisting of a cMET-directed antibody and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy.
Product Specifications
Product Name Alternative
ABBV-399
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.
Endotoxin
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Form
Liquid
Notes
For research use only. Not suitable for clinical or therapeutic use.
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
S1014-96K-HRP 200 µL
SNRPB, NT (R49) (Small Nuclear Ribonucleoprotein-associated Proteins B and B', snRNP-B, Sm Protein B/B', Sm-B/Sm-B', SmB/SmB', SNRPB1, COD) (HRP) discontinued
Ask
View Details